focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,783.50
Bid: 1,780.00
Ask: 1,780.50
Change: -29.00 (-1.60%)
Spread: 0.50 (0.028%)
Open: 1,792.50
High: 1,802.00
Low: 1,775.50
Prev. Close: 1,812.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

7 Jun 2022 17:17

RNS Number : 0571O
GSK PLC
07 June 2022
 

GSK plc (the 'Company')

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms S Jackson

b)

Position/status

SVP, Global Communications and CEO Office

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

 

 

 

 

 

 

b)

Nature of the transaction

The sale of 1,150 Ordinary Shares to facilitate a transfer into an ISA.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.2341

1,150

 

 

 

d)

Aggregated information

Aggregated volume Price

N/A (single transaction)

 

 

 

 

 

 

e)

Date of the transaction

2022-05-30

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms S Jackson

b)

Position/status

SVP, Global Communications and CEO Office

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

 

 

 

 

 

 

b)

Nature of the transaction

The purchase of 1,142 Ordinary Shares into an ISA.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.2440

1,142

 

 

 

d)

Aggregated information

Aggregated volume Price

N/A (single transaction)

 

 

 

 

 

 

e)

Date of the transaction

2022-05-30

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D Jackson

b)

Position/status

PCA of Ms S Jackson (SVP, Global Communications and CEO Office)

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

 

 

 

 

 

 

b)

Nature of the transaction

The sale of 1,150 Ordinary Shares to facilitate a transfer into an ISA.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.2460

1,150

 

 

 

d)

Aggregated information

Aggregated volume Price

N/A (single transaction)

 

 

 

 

 

 

e)

Date of the transaction

2022-05-30

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D Jackson

b)

Position/status

PCA of Ms S Jackson (SVP, Global Communications and CEO Office)

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

 

 

 

 

 

 

b)

Nature of the transaction

The purchase of 1,143 Ordinary Shares into an ISA.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.2414

1,143

 

 

 

d)

Aggregated information

Aggregated volume Price

N/A (single transaction)

 

 

 

 

 

 

e)

Date of the transaction

2022-05-30

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHSSIFMWEESEFM
Date   Source Headline
24th Jun 20223:44 pmRNSDirector/PDMR Shareholding
16th Jun 202210:58 amRNSDirector/PDMR Shareholding
10th Jun 20227:00 amRNSPositive phase III data for GSK’s RSV OA vaccine
9th Jun 20224:28 pmRNSDirector/PDMR Shareholding
7th Jun 20225:17 pmRNSDirector/PDMR Shareholding
7th Jun 202212:00 pmEQSHardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis
6th Jun 20227:00 amRNSUS FDA approval of Priorix
1st Jun 20224:55 pmRNSTotal Voting Rights
1st Jun 20221:00 pmRNSDemerger update: Publication of Documents
1st Jun 20227:00 amRNSDemerger update: Submission of Documents to FCA
31st May 20227:00 amRNSGSK to acquire Affinivax, Inc.
30th May 202210:00 amRNSFurther appointments to Designate Haleon Board
27th May 20227:00 amRNSGSK Cervarix two-dose schedule approved by NMPA
25th May 20223:41 pmPRNDirector/PDMR Shareholding
23rd May 20223:21 pmRNSDirector/PDMR Shareholding
19th May 202210:02 amRNSIain Mackay - External Appointment
16th May 20222:00 pmRNSChange of name to GSK plc
13th May 20225:13 pmRNSDirector/PDMR Shareholding
12th May 20228:58 amRNSDirector/PDMR Shareholding
11th May 20225:17 pmRNSBlock listing Interim Review
9th May 20222:53 pmRNSDirector/PDMR Shareholding
4th May 20225:49 pmRNSResult of AGM
4th May 202210:00 amRNSDirectorate Change
3rd May 20224:52 pmRNSTotal Voting Rights
27th Apr 20227:00 amRNS1st Quarter Results
26th Apr 20229:32 amRNSDirector/PDMR Shareholding
19th Apr 20227:00 amRNSDaprodustat application accepted for review by FDA
14th Apr 20222:23 pmRNSDirector/PDMR Shareholding
14th Apr 20222:15 pmRNSDirector/PDMR Shareholding
14th Apr 20221:29 pmRNSDirector/PDMR Shareholding
13th Apr 20225:11 pmRNSDirector/PDMR Shareholding
13th Apr 20229:32 amRNSDirector/PDMR Shareholding
13th Apr 20227:00 amRNSGSK agrees to acquire Sierra Oncology for $1.9bn
12th Apr 20225:10 pmRNSDirector/PDMR Shareholding
12th Apr 20224:23 pmRNSDirector/PDMR Shareholding
12th Apr 20224:00 pmRNSDirector/PDMR Shareholding
12th Apr 20223:48 pmRNSDirector/PDMR Shareholding
1st Apr 20224:03 pmRNSTotal Voting Rights
1st Apr 202211:20 amRNSGSK - segment and product sales reporting changes
28th Mar 20221:00 pmRNSPublication of 2022 AGM Notice
24th Mar 20223:22 pmRNSDirector/PDMR Shareholding
24th Mar 20222:00 pmRNSFDA update: Cabenuva oral lead-in now optional
23rd Mar 20225:03 pmRNSDirector/PDMR Shareholding
23rd Mar 20227:00 amRNSIssuance of Notes
16th Mar 20222:40 pmRNSDirector/PDMR Shareholding
15th Mar 20222:45 pmRNSDirector/PDMR Shareholding
15th Mar 202210:00 amRNSAppointments to Designate Haleon Board
11th Mar 20222:55 pmRNSDirector/PDMR Shareholding
9th Mar 20221:44 pmRNSDirector/PDMR Shareholding
8th Mar 20226:24 pmRNSGSK Annual Report 2021 on Form 20-F

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.